New Zealand - Re-Imbursed Pharmaceutical Market
Since 2014, New Zealand Re-Imbursed Pharmaceutical Market grew 0.7points year on year. With 33.1 Percent of Generics in Value in 2019, the country was number 4 among other countries in Re-Imbursed Pharmaceutical Market. New Zealand is overtaken by Turkey, which was ranked number 3 with 36.2 Percent of Generics in Value and is followed by Germany with 32.9 Percent of Generics in Value. Austria lead the ranking with 52.2 Percent of Generics in Value in 2019, that is +2.8points versus 2018. Denmark recorded the best 5 years average growth at +6.9points per year, while Slovakia witnessed the worst performance at -7.8points per year.
Loading...
| Date | Percent of Generics in Value |
|---|---|
| 2019 | 33.10 |
| 2018 | 32.70 |
| 2017 | 34.30 |
| 2016 | 31.00 |
| 2015 | 31.40 |
Download all data from 2008 to 2019
How does New Zealand rank in Re-Imbursed Pharmaceutical Market?
| # | 17 Countries | Percent of Generics in Value | Last | YoY | 5‑years CAGR | |
|---|---|---|---|---|---|---|
| 1 |
#1
Austria
|
52.20 % | 2019 | +2.8 % | +2.2 % | View data |
| 2 |
#2
United Kingdom
|
38.50 % | 2019 | +2.1 % | +2.6 % | View data |
| 3 |
#3
Turkey
|
36.20 % | 2019 | -3.7 % | +3.3 % | View data |
| 4 |
#4
New Zealand
|
33.10 % | 2019 | +1.2 % | +0.7 % | View data |
| 5 |
#5
Germany
|
32.90 % | 2019 | +1.5 % | -1.9 % | View data |